Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer ImmunotherapyGlobeNewsWire • 09/03/19
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/07/19
Will Fate Therapeutics (FATE) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/29/19
Fate Therapeutics, Inc.'s (FATE) CEO Scott Wolchko on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/08/19
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/19